Skip to main content
Chison Medical Technologies Co.,Ltd. logo

Chison Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688358 ISIN · CNE1000076R4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2022-04-18 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688358

About Chison Medical Technologies Co.,Ltd.

https://www.chison.com/

Chison Medical Technologies Co.,Ltd. specializes in the research, development, and manufacturing of diagnostic ultrasound systems. The company offers a comprehensive portfolio of medical imaging solutions, including trolley-based color Doppler systems, portable ultrasound units, and specialized handheld devices. Its products integrate advanced imaging technologies such as 4D imaging, artificial intelligence-assisted diagnostics, and high-resolution transducers to support clinical applications in cardiology, obstetrics, gynecology, and point-of-care settings. Chison focuses on delivering high-performance diagnostic tools to healthcare providers, supported by a global network of research centers and distribution channels. The company emphasizes continuous innovation in digital signal processing and transducer technology to enhance diagnostic accuracy and clinical workflow efficiency.

Recent filings

Filing Released Lang Actions
祥生医疗独立董事关于第二届董事会第十次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is titled as an independent director's opinion on various proposals discussed at the company's second board's tenth meeting. It includes opinions on remuneration schemes, appointment of auditors, profit distribution, use of raised funds, related party transactions, stock incentive plans, credit facilities, foreign exchange hedging, and cash management. The document references compliance with regulatory rules and company bylaws, and it is dated April 2022. The content is focused on board meeting agenda items and independent director opinions rather than full financial statements or detailed financial results. It does not contain comprehensive financial data or analysis typical of annual or interim reports. It is also not a simple announcement or certification but a detailed opinion on board proposals. This fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management matters.
2022-04-18 Chinese
祥生医疗关于2021年年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2021 annual profit distribution plan, including details on cash dividends per share, total dividend amount, and the need for shareholder approval at the annual general meeting. It includes board, independent directors, and supervisory board opinions on the proposal. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution plan and related approvals. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2022-04-18 Chinese
上海市通力律师事务所关于无锡祥生医疗科技股份有限公司2019年限制性股票激励计划部分已授予尚未归属限制性股票作废相关事宜之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain unvested restricted shares under the company's 2019 restricted stock incentive plan. It references relevant laws, regulations, and company approvals related to the stock incentive plan and its cancellation. The document is a standalone legal opinion on a specific corporate action related to equity incentives, not a full financial report, earnings release, or management discussion. It does not contain financial statements or comprehensive financial data. It is not an announcement of a report but a legal opinion document. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or legal documents that do not fit other categories.
2022-04-18 Chinese
国金证券股份有限公司关于无锡祥生医疗科技股份有限公司2022年度日常关联交易额度预计事项的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from a sponsoring securities company regarding the expected daily related-party transaction limits for the year 2022 of Wuxi Xiangsheng Medical Technology Co., Ltd. It includes descriptions of the transaction approval process, related party details, transaction amounts, and the impact on the company. The document is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a specialized audit or verification report related to compliance and regulatory review of related-party transactions. This fits the category of an Audit Report / Information (AR), as it involves audit opinions and regulatory compliance verification without being a full annual report or earnings release. FY 2022
2022-04-18 Chinese
祥生医疗2021年度董事会审计委员会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2021年度董事会审计委员会工作报告" which translates to "2021 Annual Board Audit Committee Work Report." It details the audit committee's activities, including reviewing financial reports, supervising external auditors, guiding internal audit work, evaluating internal controls, and coordinating communication between management and auditors. The document references compliance with regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange. It is a detailed report on audit committee work rather than a full annual report or standalone audit report. The length is 3313 characters, which is relatively short but contains substantive content about audit committee activities and oversight. This fits best with the category of Audit Report / Information (AR), which includes standalone audit reports and related audit committee work reports, excluding full annual reports. It is not a simple announcement or certification, so it is not RNS or RPA. Therefore, the classification is AR with high confidence. FY 2021
2022-04-18 Chinese
无锡祥生医疗科技股份有限公司2021年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the 2021 annual report summary of Wuxi Xiangsheng Medical Technology Co., Ltd. It contains detailed financial data for the year 2021, including total assets, net profit, revenue, quarterly financial data, shareholder information, business overview, industry analysis, and risk factors. The document includes management discussion and analysis sections and audit opinions. The length is over 12,000 characters, indicating it is a substantive report rather than a brief announcement. The content and structure align with a full Annual Report, covering company activity and full financial performance for the fiscal year 2021. Therefore, the document is classified as an Annual Report (10-K). FY 2021
2022-04-18 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.